Brief: Marksans Pharma Unit Relonchem Gets Marketing Authorization For Its Products
21/08/2024 08:04
Aug 21 (Reuters) - Marksans Pharma Ltd MARK.NS :
* MARKSANS PHARMA LTD - UNIT RELONCHEM RECEIVES MARKETING
AUTHORIZATION FOR ITS PRODUCTS
* MARKSANS PHARMA - UNIT GETS MARKETING AUTHORIZATION FOR
FLUOXETINE 10MG, 30MG, 60MG CAPSULES
Source text for Eikon: ID:
Further company coverage: MARK.NS
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Marksans Pharma
See all newsIndia's Marksans Pharma jumps to over 18-month high after more than doubling quarterly profit
Brief: Marksans Pharma Ltd To Acquire 100% Of Netherlands-Based Qliniq B.V
India's Marksans Pharma jumps to 10-month high after Q4 profit rise
Brief: Marksans Pharma March-Quarter Consol Net Profit 1.48 Billion Rupees
Brief: Marksans Pharma Ltd Receives USFDA Approval For Benzonatate Capsules USP, 100 Mg & 200 Mg